You will remember in March we announced our success in securing funding of £65,000 for a Senior Medicinal Chemist to start work with the FOP Research team at the University of Oxford. The chemist will have the challenge of taking the Oxford FOP Research Team's drug designs and turning them into optimised drug candidates.
Well we are excited to announce (a little late) the employment of Dr Aicha Boudhar who was selected from over 60 applicants. Dr Boudhar will be working closely with Dr Paul Brennan and Dr Alex Bullock on creating new drug candidates in the search for possible treatments for FOP.
Dr Aicha Boudhar received her training at the University of Strasbourg before undertaking a position at the National University of Singapore working on medicinal chemistry for anti-malarial compounds. She has also gained industrial experience through several internships. She joined the University of Oxford FOP Research Team on Monday 18th August and will be directly supervised by Dr Paul Brennan with additional project supervision from Dr Alex Bullock. Her chemistry work will be undertaken alongside other members of FOP research team in the in the chemistry laboratory in the newly opened Target Discovery Institute in Oxford.
Dr Paul Brennan received his training at the University of California, Berkeley and undertook his first academic position at the University of Cambridge in the UK. Subsequently, he gained significant experience in the drug industry at Amgen and Pfizer, including work on kinase inhibitors relevant to FOP. Following the closure of the Pfizer site in Sandwich, Paul joined the SGC consortium at the University of Oxford where he works closely with the current University of Oxford FOP Research Team.
Dr Boudhar will also be joining Dr Bullock, Professor Triffit and Chris Bedford-Gay at the IFOPA organised FOP Drug Development Forum being held this Novemeber in Boston.